Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial - Nicholls, Stephen J; Nissen, Steven E; Fleming, Cynthia; Urva, Shweta; Suico, Jeffrey; Berg, Paul H; Linnebjerg, Helle; Ruotolo, Giacomo; Turner, P. Kellie; Michael, Laura F (JAMA : the journal of the American Medical Association, 2023)
Keywords: Administration, Oral; Adolescent; Adult; American Indian or Alaska Native; Aorta; Aortic stenosis; Apolipoproteins; Apoprotein(a) - antagonists & inhibitors; Arteriosclerosis; Atherosclerosis; Biomarkers; Black or African American; Cardiovascular Agents - administration & dosage; Cardiovascular Agents - adverse effects; Cardiovascular Agents - therapeutic use; Clinical significance; Clinical trials; Dosage; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; Female; Females; Health services; Humans; Hypolipidemic Agents - administration & dosage; Hypolipidemic Agents - adverse effects; Hypolipidemic Agents - therapeutic use; Inhibitors; Lipoprotein(a) - antagonists & inhibitors; Male; Middle Aged; Online First; Oral administration; Pharmacodynamics; Pharmacokinetics; Placebos; Plasma levels; Plasminogen; Preliminary Communication; Racial Groups; Reduction; Safety; White; Young Adult; United States--US; Alaska